Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL4I1 | Q96RQ9 | 6/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30947947 | 0.83 | IL4I1 (0.57) | IL4I1POLBHRH3LMNAIDH1 | |
| SCHEMBL30947924 | 0.83 | IL4I1 (0.57) | IL4I1POLBHRH3LMNAIDH1 | |
| SCHEMBL30948068 | 0.81 | IL4I1 (0.60) | IL4I1POLBHRH3IDH1 | |
| SCHEMBL30948278 | 0.81 | IL4I1 (0.60) | IL4I1POLBHRH3IDH1 | |
| SCHEMBL27163079 | 0.80 | IL4I1 (0.74) | IL4I1POLBHRH3TP53RXFP1 | |
| SCHEMBL30948164 | 0.78 | IL4I1 (0.60) | IL4I1POLBHRH3TP53RXFP1 | |
| SCHEMBL27163306 | 0.78 | IL4I1 (0.77) | IL4I1POLBHRH3TP53RXFP1 | |
| SCHEMBL30948287 | 0.76 | IL4I1 (0.50) | IL4I1POLBHRH3HSD11B1 | |
| SCHEMBL30947910 | 0.72 | IL4I1 (0.60) | IL4I1HRH3HSD11B1 | |
| SCHEMBL30948080 | 0.70 | IL4I1 (0.58) | IL4I1POLBTP53RXFP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | IL4I1 1/4885POLB 2929/4885HRH3 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.